AI Article Synopsis
- - The study focuses on how multiple myeloma progression is influenced by interactions between malignant plasma cells and myeloid-derived suppressor cells (MDSCs), particularly the role of CD304 and galectin-1 during autologous stem cell transplantation (ASCT).
- - Findings show higher CD304 expression on circulating monocytic MDSCs before ASCT, linking it to higher galectin-1 levels in serum, and suggest that galectin-1 expands and activates pre-ASCT MDSCs, which are tied to worse patient outcomes.
- - The research also reveals that blocking galectin-1 and CD304 can potentially reduce MDSC activity and support the body's immune response against multiple myeloma, indicating a critical pathway
Article Abstract
Progression of multiple myeloma is regulated by factors intrinsic to the clonal plasma cells (PC) and by the immune effector cells in the tumor microenvironment. In this study, we investigated the interaction between CD304 expression on myeloid-derived suppressor cells (MDSC) and galectin-1 from malignant PCs in the context of autologous stem cell transplantation (ASCT) for multiple myeloma. Using high-throughput screening, CD304 expression on circulating monocytic MDSCs (M-MDSC; CD14HLA-DR) was compared before and after ASCT. There was a significantly higher M-MDSC expression of CD304 before ASCT and a clear correlation between circulating pre-ASCT M-MDSC frequency and serum galectin-1 concentration. Treatment of pre-ASCT M-MDSCs, but not post-ASCT M-MDSCs, with galectin-1 expanded the M-MDSC population and increased expression of CD304. High galectin-1 expression by malignant PCs was associated with poor clinical outcomes. M-MDSC development and expression of CD304 were differentially induced when healthy donor peripheral blood mononuclear cells were cultured with the human multiple myeloma cell lines RPMI-8226 and JJN3, which express high and low galectin-1, respectively. Inhibition of galectin-1 reduced M-MDSC proliferation induced by RPMI-8226 cells but not by JJN3 cells, and blockade of CD304 reduced M-MDSC migration induced by RPMI-8226 cells but not by JJN3 cells. In addition, blockade of CD304 reversed suppression of the cytotoxic effect of melphalan by pre-ASCT M-MDSCs. Our data demonstrate that multiple myeloma-derived galectin-1 could mediate the tumor-promoting effect of M-MDSCs through its interaction with CD304 on M-MDSCs and contribute to multiple myeloma progression after ASCT..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/2326-6066.CIR-20-0663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel insights into the circ_0003489/let-7b-5p/GLUT1 axis and its possible role in multiple myeloma.
Transpl Immunol
December 2024
Department of Pharmacy, Zhongshan Hospital Xiamen University, Xiamen 361004, Fujian, China. Electronic address:
Background: Circular RNAs (circRNAs) act as vital players in multiple myeloma (MM). Herein, we focused on the function of hsa_circ_0003489 (circ_0003489) in MM development and bortezomib (BTZ) resistance.
Methods: Relative RNA levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR).
Comparison of thrombopoietin receptor agonists plus recombinant human thrombopoietin vs. recombinant human thrombopoietin alone for hematopoietic reconstruction in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
Transplant Cell Ther
December 2024
Xi'an Jiaotong University Second Affiliated Hospital, China.
Background: Hetrombopag is a novel thrombopoietin receptor agonist that has shown an additive effect in stimulating platelet production when combined with recombinant human thrombopoietin (rhTPO). But it remains unclear whether this combination can promote hematopoietic reconstruction after autologous stem cell transplant (ASCT).
Purpose: To compare the effect of recombinant human thrombopoietin (rhTPO) plus thrombopoietin receptor agonists (TPO-RA) versus rhTPO alone on hematopoietic recovery, adverse events, post-operative complications, and cost effectiveness in patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplant (ASCT).
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma.
Blood Cancer J
December 2024
Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood. We analyzed 528 MM patients who presented to our institution between 2014 and 2021 and who had undergone molecular testing.
View Article and Find Full Text PDFAmyloidosis of the Tongue in Multiple Myeloma.
Br J Dermatol
December 2024
Department of Stomatology, The First People's Hospital of Lianyungang, 6 East Zhenhua Road, Haizhou District, Lianyungang 222061, Jiangsu Province, China.
Impact of liquid-liquid phase separation- and immune-related gene signatures on multiple myeloma prognosis: focus on DDX21 and EZH2.
Hematology
December 2025
Department of Hematology, Shaoxing Shangyu people's Hospital, Shaoxing, People's Republic of China.
Objective: Liquid-liquid phase separation (LLPS) may affect the therapeutic sensitivity of multiple myeloma (MM). This study aimed to identify LLPS-related genes with MM prognostic values and to confirm their effects on tumor progression.
Methods: Based on public transcriptomic data, this study screened LLPS- and immune-related genes for MM-derived plasma cells.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!